PALO ALTO, Calif., April 9, 2018–Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development services, announced a collaboration with Ranomics to offer online access to its mutagenesis platform to scientists around the globe.
Ranomics is a Toronto-based biotechnology company whose mission is to enable transformative discoveries using genomics. The VariantFind™platform offers unique mutagenesis services to build comprehensive variant libraries on complex and long DNA sequences, enabling its partners to make breakthrough discoveries.
“We are proud to team up with Science Exchange, a move that will give life sciences communities all over the world quick and easy access to quality science,” says Leo Wan, Ph.D., CEO and co-founder of Ranomics. “Our core strength has always been building cost-effective and diverse DNA libraries rapidly. Now we can effectively assist customers who want to use these libraries in high-throughput cell-based assays as part of a more full-service approach to pre-clinical research.”
“We are thrilled to partner with Ranomics to make its innovative gene mutagenesis services available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is always looking to add innovative and qualified providers to our platform, giving scientists quick access to a comprehensive selection of research services. Ranomics has impressed us with their superb progress in mutagenesis and cell-based screening.”
About Ranomics Ranomics is a Toronto-based biotechnology company whose mission is to enable transformative discoveries using genomics. Ranomics’s proprietary functional genomics platform offers unparalleled ability to study genetic variations within the context of fundamental biology and drug discovery. The platform promotes unbiased and systematic characterization of gene variations, leading to the development of novel therapeutics in a derisked and cost-effective manner. The VariantFind™ technology is a key component of Ranomics’s functional genomics platform, and offers unprecedented scalability and flexibility in building DNA variant libraries. The VariantFind™technology is used by partners to find meaningful variants in their research programs that will propel discovery and make better products. Ranomics is committed to providing top-quality variant libraries at competitive costs with quick turnaround time for all partners. Ranomics is an alumnus of IndieBio and graduate of JLabs Toronto.
Start finding target gene variations today! Request a quote at the Ranomics storefront:
Most everyone knows that precision medicine promises to transform the healthcare landscape, delivering powerful and personalized treatments for previously intractable diseases. Even so, biotech innovators still face tremendous hurdles in realizing this promise — chief among them, finding access to sufficient numbers of annotated, characterized and consented patient samples.
Novaseek Research has developed a unique solution to this dilemma: the Clinical Data Network for Research platform — otherwise known as CDNR.
CDNR provides instant access to thousands of ethically-sourced patients’ specimens and associated real-world clinical data in pursuit of advancing the field of personalized medicine. Novaseek obtains biosamples and associated data through its extensive network of physicians, clinical labs, and hospitals. Within this network, Novaseek actively recruits patients to match targeted research needs. Novaseek also maintains a large searchable database of de-identified clinical information representing millions of patients.
Through the Novaseek platform, researchers can easily obtain the data they need throughout the product life cycle. For instance, researchers seeking the statistics necessary for in vitro diagnostics submissions can gain access to sufficient numbers of annotated, characterized and consented patient samples and related data. With CDNR, obtaining clinical data and biospecimens is seamlessly integrated into R&D.
PEAKS AB: The Fastest Path to Accurate Antibody Sequences
What challenges do you face in characterizing monoclonal antibodies (mAbs) at the molecular level? Whether it’s heterogeneity caused by truncation or glycation, or confounding isobaric amino acids, you’ve wished there was a better way.
Watch our webinar to learn about a novel, three-in-one solution for obtaining 100% accurate amino acid sequences for antibody proteins, powered by the PEAKS AB software.
You will learn about:
Intact mass analysis of antibody proteins; why is it important?
Isoleucine and leucine differentiation by using EThcD fragmentation methods
About Our Speaker
Wen Zhang, Ph.D. is the Senior Application Scientist at Bioinformatics Solutions Inc. (BSI). With her rich experience in proteomics and MS data generation, processing and analysis, she joined BSI, where she now leads the antibody protein de novo sequencing projects. Her work includes intact mass, de novo sequencing, peptide mapping, post-translational modification, disulfide bond and N-linked glycan analyses.
Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development services, announced a collaboration with Murray Rheology Consulting to offer online access to its rheology training, problem-solving, and technical writing services to scientists and engineers around the globe.
Murray Rheology Consulting is an LLC based in West Lafayette, Indiana, USA, whose mission is to help researchers and industrial scientists who are developing soft materials by providing them with rheological analysis and test method development services.
“Science Exchange is our platform of choice because of its worldwide reach and dedication to helping life science labs connect with specialists,” says Lisa R. Murray, Ph.D., General Manager and Lead Consultant of Murray Rheology Consulting. “Science Exchange helps us stay engaged with our clients, so that we can better design customized test methods for their product development, quality control, and research. Our firm is passionate about helping other companies overcome barriers to fluid and gel scale-up so that their products can reach the market faster.”
“We are thrilled to collaborate with Murray Rheology Consulting to make its rheology consulting services readily available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is dedicated to adding innovative and qualified providers to our platform, giving scientists quick access to a comprehensive selection of research resources. Murray Rheology Consulting met our rigorous qualification criteria while demonstrating in-depth expertise in the field of rheology.
About Murray Rheology Consulting
Murray Rheology Consulting was founded in 2017 with a focus on giving industrial scientists training and advice for improving soft material development. Current projects include online rheology training for technicians, engineers, and scientists along with technical reviews for biomedical rheological test designs. Our PhD rheologist provides custom trainings and onsite consultation. The wide assortment of industries assisted by Murray Rheology Consulting brings creative approaches to our analyses and solutions. From colloids to hydrogels to emulsions, we handle the planning and analyses of physical properties to solve problems. Murray Rheology Consulting can be found on Twitter @MurrayRheology.
Connect with Murray Rheology Consulting today to discuss your product development program’s biorheology testing requirements — click “Request Quote” to describe your project!
Science Exchange shortlisted in two categories – Best New Procurement Consultancy Project and Best P2P Specialist Provider
PALO ALTO, CA, March 30, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, today announced it has been named a finalist in two categories for the esteemed World Procurement Awards, the most sought-after and recognized accolade in procurement, run by Procurement Leaders. Alongside industry leaders like Microsoft, Coupa, IBM, and KPMG, Science Exchange is on the shortlist for two awards: Best New Procurement Consultancy Project, with pharmaceutical client GlaxoSmithKline (GSK) Consumer Health, and Best Procure-to-Pay (P2P) Specialist Provider.
Science Exchange was recognized for its P2P platform, which empowered procurement teams and increased R&D operational efficiency at GlaxoSmithKline Consumer Health (GSK-CH) and another major global pharmaceutical client with rapid access to innovation through outsourced R&D.
“We are honored to be recognized once again by Procurement Leaders for the work we are doing with our clients to help accelerate breakthrough discoveries,” said Dr. Elizabeth Iorns, Ph.D., CEO and Co-Founder of Science Exchange. “Outsourcing with scientific service providers is crucial for increasing R&D efficiency, but finding and qualifying providers can be a time-consuming process. Our platform accelerates scientific breakthroughs by connecting researchers to thousands of scientific services from a network of thoroughly vetted providers.”
The winners of the awards will be announced on May 17, 2018 at the World Procurement Awards Ceremony in London, England. To find out more and see a list of all the finalists, visit the website at www.worldprocurementawards.com.
Best New Procurement Consultancy Project
In the category Best New Procurement Consultancy Project, GlaxoSmithKline Consumer Health (GSK-CH) implemented Science Exchange to increase the productivity of their R&D operations. Through the Science Exchange platform, GSK-CH researchers gained instant access to the 2,500+ outsourced service providers on the Science Exchange network, including niche and innovative technologies. Science Exchange was able to broaden the GSK-CH R&D organization’s geographical reach, capitalize on local demand, help spur innovation, and advance their timelines to bring products to market faster. Some of the results included an 11% increase in GSK-CH’s access to innovative providers (YTD) and 44 new niche providers selected by GSK-CH during scouting efforts this year.
Read More
Best P2P Specialist ProviderIn the category Best P2P Specialist Provider, a leading global pharmaceutical company explored the potential to increase their R&D productivity by using the Science Exchange technology platform to improve its outsourcing processes. Instead of spending hours a day exploring service providers, the scientists logged into Science Exchange and quickly reviewed service provider satisfaction ratings, secured competitive quotes, and selected a supplier to meet their research needs.After one year of using Science Exchange, this global pharmaceutical company’s preclinical services group reported that scientists saved 1,300 hours, the legal and procurement teams saved 2,730 hours, and the combined time-savings translated to hundreds of thousands of dollars in cost savings.
About World Procurement Awards The World Procurement Awards, in association with SAP Ariba, are the most celebrated and sought-after awards in procurement, representing the best projects, people and organizations across the world. They reward the collective efforts of individuals and teams and are an affirmation of the hard work, innovation and dedication of those at the forefront of this dynamic global profession.This year saw a record number of entries from some of the most influential companies across 36 countries for the 12th annual awards. The judges were impressed with the sheer quality of this year’s submissions, commenting that the bar had once again been raised, with innovation at the heart of each project as teams across the globe work hard to position themselves as valuable business partners.
Learn more about how Science Exchange can help your organization accelerate innovation through outsourced R&D — request a demo of our platform today.
Scientific research is advancing without pause; innovations are emerging at a breathtaking rate all over the world through the endeavors of diverse scientific disciplines. The future of scientific research is set on an unpredictable course teeming with both excitement and unease — whether AI-enabled tools will reshape drug discovery or if “patient-on-a-chip” technology will let future scientists create custom therapies for patients on the spot remains to be seen. Amidst the uncertainty, one thing remains clear: Science Exchange will be your fastest path to accessing new and emerging research tools, technologies, and services as the future continues to unfold.
A moment’s time is all you need to learn about the benefits of five promising technologies that may play an integral role in the near future. Sit back and Take 5! If something grabs your interest, click on the provided link to learn more about each service.
NanoMIPS
These novel affinity reagents, sometimes called “plastic antibodies,” have similar specificity to antibodies and can replace antibodies in in vitro applications, including sensing, imaging, purification, analysis, and diagnostics.
NanoMIPs are nanostructured Molecularly Imprinted Polymers, which typically contain a single binding site to a template molecule. NanoMIPs are prepared via a proprietary imprinting process that involves the self-assembly of binding monomers around a target template—these monomers are then polymerized to generate a “synthetic receptor” with high affinity and specificity to the template.
This next-generation chemical modification platform provides a superior alternative to CRISPR, siRNA, and shRNA approaches, and can be used to silence or regulate different RNA modalities.
Unlike conventional technologies, FANAs have high fidelity for the RNA target and highly reduced off-target effects (no RISC-associated off-target effects). These attributes represent a more potent, efficient, and cost-effective solution for RNA silencing and regulation.
This translational intestinal screening multi-well platform simulates the human colonic microbiota conditions in vitro and helps identify the pharmacological compounds metabolized by intestinal microbiota.
The Netherlands Organization (TNO)’s i-screen service enables rapid identification of drugs that are susceptible to metabolism by intestinal microbiota. Additionally, it can be used to identify unknown metabolites transformed by intestinal microbiota.
This service enables comprehensive profiling of up to 800 total and phosphoproteins from cell and tissue samples, using just 20–60 μg of protein.
Unlike other protein-profiling technologies, DigiWest allows in-depth analyses of cell signaling pathways on the level of phosphorylated proteins. As such, DigiWest adds significant value to biomarker identification, precision medicine, compound characterization, and mode-of-action studies.
This unique service is based on a patent-pending biological clearing agent called Visikol™ that penetrates tissue and renders it transparent without causing structural damage.
The assay has applications in the fields of toxicology, preclinical drug development, clinical diagnostics, basic research and plant biology, as tissues can be easily visualized in 3 dimensions.
PALO ALTO, CA, March 6, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development services, announced a collaboration with PhenoSwitch Bioscience to offer online access to its mass spectrometry (LC-MS/MS) services, including SWATH™ proteomics offerings to scientists around the globe.
PhenoSwitch Bioscience is a Quebec, Canada-based contract research organization (CRO) whose mission is to help scientists elevate their research projects with innovative mass spectrometry solutions, in a collaborative manner.
“We are proud to team up with Science Exchange as we share similar philosophies: giving scientists quick and easy access to quality science,” says Hugo Gagnon, Ph.D., CEO and co-founder of PhenoSwitch Bioscience. “Our continuous internal mission to optimize our workflows, attentive listening to our client’s needs and careful scientific revisions are the keys to our success when offering complex services like LC-MS/MS and SWATH™ omics. Moreover, being a small, multidisciplinary scientific team allows us to be flexible and able to accommodate custom requests.”
“We are excited to collaborate with PhenoSwitch Bioscience to make its mass spectrometry services readily available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is heartily committed to adding innovative and qualified providers to our platform, giving scientists quick access to a comprehensive selection of research services. PhenoSwitch Bioscience met our rigorous qualification criteria while demonstrating breakthrough discoveries in the field of drug development, biomarker discovery and fundamental science.”
About PhenoSwitch Bioscience
PhenoSwitch Bioscience Inc. was established in 2013 with the goal of providing expert services in mass spectrometry to major actors in the life science research industry. Today, PhenoSwitch uses the 20+ years of combined life science research experience of its Ph.D. level scientists to help solve research and/or drug discovery problems with modern mass spectrometry approaches. Our team’s commitment and in-depth understanding of mass spectrometry brought us among the world’s leaders in SWATH™ omics technology. We have also grown a unique expertise in the development of high sensitivity micro-flow LC-MS/MS methods. Apart from our proteomics, lipidomics and metabolomics services, we also offer several pre-developed targeted quantitative panels as well as custom methods development for small and large molecules bioanalysis in complex matrices. Follow the company on Twitter @PhenoSwitch.
Interested in learning more about PhenoSwitch Bioscience’s technologies? Request a quote to receive information:
PALO ALTO, CA, March 12, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced a partnership with PhenoVista Biosciences to offer online access to its Phenotypic Assay Development Services to scientists around the globe.
“Science Exchange has been a steadfast ally of ours since we founded PhenoVista back in 2014. They have always understood the strength of our quantitative imaging-based approach and immediately recognized the great strides our scientists make to deliver the highest quality data possible. We’re very excited about taking our relationship with Science Exchange to the next level and look forward to working with new groups of scientists across the globe.” says James G. Evans, Ph.D., CEO and Founder of PhenoVista Biosciences. PhenoVista Biosciences is a San Diego, California-based CRO and is the leading provider of custom phenotypic assay services. The company’s mission is to enrich the drug discovery community with high-quality information derived from physiologically relevant cell models. PhenoVista specializes in custom assay development in a wide range of therapeutic areas, including CNS, immuno-oncology, and rare diseases.
“We’re delighted to strengthen our partnership with PhenoVista to ensure that their cutting-edge assay services can be made more easily available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is committed to adding the most innovative and qualified providers to our platform, so scientists have the secure services they need readily available to aid their discoveries. PhenoVista met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of phenotypic assays.”
About PhenoVista Biosciences
PhenoVista is the leading provider of custom imaging-based phenotypic assay services. With a collaborative and scientifically-driven project design and management approach, PhenoVista has a proven track record of delivering high quality data from robust and scalable assays. A key advantage that PhenoVista leverages is the ability of their industry-trained scientists to combine world-class understanding of diverse biological systems, with cutting-edge quantitative imaging to deliver clear, actionable output data. PhenoVista’s clients include the majority of top-20 pharmaceutical companies as well as numerous VC-funded biotechnology start-ups. PhenoVista was founded by Dr. James G. Evans and Dr. Anthony Essex in 2014. A privately funded and revenue-driven company, PhenoVista continues to see double-digit revenue growth year over year.
Connect with the PhenoVista team by requesting a quote on their storefront today!
Combining Gene Editing and iPSC Technologies
for Preclinical Discovery and Translational Research
Watch our webinar on-demand to hear Ruby Chen-Tsai, Ph.D., CSO of Applied StemCell, discuss how her team is using genome engineering and iPSC technologies to advance disease modeling, lead compound discovery, and bioproduction.
You will learn about:
Using genome engineering technologies for the generation of preclinical research models
How genome editing technologies can be applied to the development of cell and gene therapies
Application of gene editing to bioproduction
CRISPR-mediated gene editing for the development of nucleic acid reference standards
About Our Speaker
Ruby Yanru Chen-Tsai, Ph.D. has worked on the development and modification of stem cells and pre-clinical models for over 25 years. Prior to Applied StemCell, Dr. Chen-Tsai was at Stanford University, where she served as Director of the Transgenic Research Center and Associate Director of the Stanford Cancer Institute. Dr. Chen-Tsai is a co-inventor of the TARGATT™ integrase technology and the “DICE” platform for site-specific gene insertion. Her current research focuses on pre-clinical model development, as well as gene- and stem cell-based therapies using genome editing technologies including CRISPR/Cas9 and TARGATT™ integrase.
PALO ALTO, CA, March 6, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development services, announced a partnership with CARE Research, LLC to offer online access to its preclinical services to scientists around the globe.
CARE Research, LLC is a Colorado-based contract research organization (CRO) and a foremost provider of preclinical research. The company’s mission is to deliver services that are competitively priced, of superior quality, and rendered with a high degree of responsiveness that ensures ease of FDA approval.
“Our partnership with Science Exchange allows us to widen our operational reach and to find clients we wouldn’t have connected with had we only used our internal resources,” said Rajan Bawa, Ph.D., co-founder and CEO of CARE Research, LLC. “Additionally, the project managers with whom we have interacted are very responsive, helpful and easily available to answer any questions and facilitate sponsor interactions.”
“We are excited to partner with CARE Research, LLC to make its preclinical in vivo services readily available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is steadfastly committed to adding new innovative and qualified providers to our platform, so scientists have quick access to a breadth of research services. CARE Research, LLC met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of in vivo research.”
About CARE Research, LLC
CARE Research, LLC is a leader in customized preclinical studies with quick turnaround, competitive costing and humane animal handling procedures under strict regulatory compliance. Our experienced, hands-on scientists design and conduct studies that facilitate regulatory approval. Our studies enable both large and small life science companies to achieve their design and exploration goals as well as obtain marketing approval. Our services include a wide range: PK/ MTD, DART, toxicology, IND/NDA enabling studies for drugs and biomedical devices. Our clinical pathology and histopathology capabilities afford a single point of control to our study sponsors. We offer a variety of animal models including rodents, rabbits, dogs, guinea pigs, pigs, mini pigs, goats, sheep, cattle, and horses.
Need animal studies? Submit your preclinical study scope of work to receive a quote from the CARE Research team:
Follow Us